Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash & Equivalents data on file, last reported at $71.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $71.2 million, down 6.22% year-over-year; the trailing twelve-month figure through Feb 2026 was $71.2 million (down 6.22% YoY), and the FY2025 annual result was $247.0 million, up 124.52% from the prior year.
• Cash & Equivalents declined to $71.2 million in Q1 2026 per NRIX's latest filing, from $247.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $247.0 million in Q4 2025 and troughed at $33.6 million in Q1 2023.
• A 5-year average of $79.7 million and a median of $71.2 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 77.93% in 2022, then soared 134.12% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $64.5 million in 2022, then slipped by 15.27% to $54.6 million in 2023, then soared by 101.36% to $110.0 million in 2024, then jumped by 124.52% to $247.0 million in 2025, then tumbled by 71.17% to $71.2 million in 2026.
• Business Quant data shows NRIX's Cash & Equivalents at $71.2 million in Q1 2026, $247.0 million in Q4 2025, and $78.4 million in Q3 2025.